TriangleNCT00602667 · OUTCOME
Percentage of Patients With Objective Responses Rate to Induction Chemotherapy
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of patients
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From on-study date to 2 months after completion of induction chemotherapy (up to 4 months after on-study date)
What was measured
For patients treated in the intermediate and high risk strata with residual or metastatic disease we will estimate the stratum-specific objective response rate (complete response (CR) or partial response \[ PR\]). All patients who receive at least 1 -dose of methotrexate are evaluable for response. Objective responses must be sustained for at least eight weeks.
Analysis population: Eligible intermediate and high risk group patients who received at least 1 dose of methotrexate were included in this analysis. One of the high risk patients did not start therapy and was excluded.
Groups in this outcome
Intermediate-Risk Group
Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease
High-Risk Group
Patients with central nervous system (CNS) metastatic disease
| Group | Source count |
|---|---|
| Intermediate-Risk Group | 156 |
| High-Risk Group | 76 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Intermediate-Risk Group | 58.3 | Not reported | 50.2 | 66.2 | Not reported |
| High-Risk Group | 21.1 | Not reported | 12.5 | 31.8 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 50.2
- upper Limit
- 66.2
- value
- 58.3
- group Id
- OG001
- lower Limit
- 12.5
- upper Limit
- 31.8
- value
- 21.1
- denoms
- counts
- group Id
- OG000
- value
- 156
- group Id
- OG001
- value
- 76
- units
- Participants
- description
- For patients treated in the intermediate and high risk strata with residual or metastatic disease we will estimate the stratum-specific objective response rate (complete response (CR) or partial response \[ PR\]). All patients who receive at least 1 -dose of methotrexate are evaluable for response. Objective responses must be sustained for at least eight weeks.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease
- id
- OG000
- title
- Intermediate-Risk Group
- description
- Patients with central nervous system (CNS) metastatic disease
- id
- OG001
- title
- High-Risk Group
- param Type
- NUMBER
- population Description
- Eligible intermediate and high risk group patients who received at least 1 dose of methotrexate were included in this analysis. One of the high risk patients did not start therapy and was excluded.
- reporting Status
- POSTED
- time Frame
- From on-study date to 2 months after completion of induction chemotherapy (up to 4 months after on-study date)
- title
- Percentage of Patients With Objective Responses Rate to Induction Chemotherapy
- type
- SECONDARY
- unit Of Measure
- Percentage of patients
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice